Mirion Technologies (MIR) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $206.8 million, up 8.2% year-over-year, with adjusted EBITDA of $45.7 million and adjusted EPS of $0.08, driven by strong nuclear power and medical segment demand.

• Margin expansion continued for the fifth consecutive quarter, with adjusted EBITDA margin at 22.1%.

• Net loss for Q3 2024 was $14.0 million, slightly higher than $12.9 million in Q3 2023; nine-month net loss improved to $52.5 million from $84.2 million year-over-year.

• The company benefited from generational trends in nuclear power, cancer care, and robust macro tailwinds.

• Strategic alliances were signed with Siemens Healthineers and Varian for radiation therapy software solutions.

Financial highlights

• Q3 2024 revenue was $206.8 million, up from $191.2 million in Q3 2023; organic revenue grew 6.1% year-over-year.

• Adjusted gross profit rose 16.5% to $107.6 million, with gross margin improving to 52.1%.

• Adjusted EBITDA increased 17.8% to $45.7 million; margin expanded to 22.1%.

• Adjusted EPS was $0.08, up from $0.05 in Q3 2023.

• Q3 backlog stood at $815 million, with net cash from operating activities for the nine months at $38.3 million.

Outlook and guidance

• 2024 revenue growth expected at 6–7% (organic 5–6%), with adjusted EBITDA guidance at $195–$205 million and adjusted EPS at $0.37–$0.42.

• Adjusted free cash flow guidance narrowed to $65–$75 million.

• Leverage expected to end 2024 at 2.6x, down from 2.9x at quarter-end.

• Medical segment organic growth expected to be low single digits; Technologies segment mid-single digits.

• Management expects adequate liquidity for the next 12 months, supported by operating cash flow and credit facilities.